Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amgen Inc To Pay $762 Million In Marketing Case-Reuters

Tuesday, 18 Dec 2012 01:14pm EST 

Reuters reported that Amgen Inc in a New York federal court for improper marketing practices involving its once top-selling Aranesp anemia drug, and prosecutors said the Company has agreed to pay $762 million in a civil settlement and criminal fines. Federal prosecutors said in court that the Company had agreed to pay $612 million in a civil settlement, a $14 million criminal forfeiture payment, and a $136 million criminal fine. 

Company Quote

-0.2 -0.15%
19 Aug 2014